Name | Amelparib |
---|---|
Synonyms |
R252S84C2I
Benzo[h][1,6]naphthyridin-5(1H)-one, 10-ethoxy-2,3,4,6-tetrahydro-8-(4-morpholinylmethyl)- Amelparib 10-Ethoxy-8-(4-morpholinylmethyl)-2,3,4,6-tetrahydrobenzo[h][1,6]naphthyridin-5(1H)-one |
Description | Amelparib (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM; does not affect cell viability up to 1 mM in rat cortical neuronal cells; attenuates PARP activity restores ATP and NAD+ levels in oxygen glucose deprived (OGD) rat cortical neurons, reduces apoptosis-associated molecules such as apoptosis inducing factor (AIF), cytochrome C and cleaved caspase-3 in the OGD model; JPI-289 is a potential neuroprotective agent which could be useful as a treatment for acute ischaemic stroke. Stroke Phase 2 Clinical |
---|---|
References | References 1. Kim Y, et al. Clin Exp Pharmacol Physiol. 2017 Jun;44(6):671-679. 2. Kim Y, et al. Mol Neurobiol. 2018 Jan 30. doi: 10.1007/s12035-018-0910-6. View Related Products by Target PARP Stroke |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 569.6±50.0 °C at 760 mmHg |
Molecular Formula | C19H25N3O3 |
Molecular Weight | 343.420 |
Flash Point | 298.3±30.1 °C |
Exact Mass | 343.189606 |
LogP | 1.04 |
Vapour Pressure | 0.0±1.6 mmHg at 25°C |
Index of Refraction | 1.624 |